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Scientific Note
Abstract
Colorectal cancer (CRC) is predominantly a disease of elderly and is a major cause of morbidity and mortality in the elderly
population. The increased availability of treatment options for CRC has made it more difficult for clinicians to decide on the
optimal therapeutic approach in elderly patients, because of the potential for poorer outcomes due to an increased burden of
comorbidities, functional dependency, and limited life expectancy. It is necessary to determine which elderly patients are likely
to benefit from active cancer therapy, and the establishment of treatment markers for multimodality approaches is eagerly
awaited. Elderly cancer patients are at risk of exposure to various intrinsic inflammatory mediators, such as tumor-generating
cytokines and surgery-induced pro-inflammatory cytokines. It is therefore important to understand the immunological changes
occurring in the elderly and to adjust treatment strategies accordingly to reduce the morbidity and mortality associated with
multimodality therapy for CRC that induce systemic inflammation. Several inflammation-based factors such as the Glasgow
Prognostic Score (GPS) may reflect the balance between tumor progression and host-related immunity, especially in elderly
CRC patients. Appropriate selection criteria for multimodality therapy in elderly CRC patients may include not only tumor
characteristics, but also host- and/or treatment-related factors such as comorbidities or surrogate markers using inflamma-
tion-based factors.
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Introduction
The elderly population is increasing rapidly in developed
countries, and cancer remains a major public health problem
affecting more elderly than younger individuals. Clinicians
need to evaluate elderly cancer patients carefully, because of
the increased likelihood of comorbidities and age-specific
organ-function deterioration, both of which have implica-
tions for cancer therapy. Colorectal cancer (CRC) is the
commonest malignancy worldwide, and is largely a disease
of the elderly. Various treatment modalities have been used
to prolong survival in patients with CRC, including surgery,
radiotherapy and chemotherapy, and this multimodal thera-
peutic approach to CRC represents a good role model for the
medical and social optimization of cancer treatments in el-
derly patients.
Surgery is the mainstay of CRC treatment; however, modern
chemotherapy with molecular-targeted agents has increased
the survival time to more than 2 years, even in patients with
inoperable metastases. Recent multimodal approaches in-
volving chemotherapy, radiotherapy and surgery for primary
and/or metastatic lesions, alone or in combination, have been
proposed to prolong the survival of patients with advanced
CRC even further. However, the increased availability of
treatment options has made it more difficult for clinicians to
decide on the optimal therapeutic approach, especially in
elderly patients.
The elderly CRC population is a heterogeneous group, in-
cluding patients with an otherwise excellent health status, as
well as those with comorbid conditions, functional depend-
ency, and limited life expectancy. Elderly patients are there-
fore sometimes undertreated compared with younger pa-
tients, because of clinician preferences. Published results for
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surgical morbidity and mortality, and for the safety of chem-
otherapy in elderly patients with CRC are also conflicting, 1, 2
and scientific evidence for the efficacy of modern multimo-
dality therapy in advanced CRC is scarce. However, we re-
cently published the results of a study involving the treat-
ment of elderly patients with multimodality therapy for
metastatic or recurrent CRC.3
Some of the elderly patients derived as much benefit from
aggressive multimodality therapy as younger patients. The
prognostic factors for elderly patients were host- and treat-
ment-related, whereas the prognostic factors for younger
patients were tumor-related. This evidence suggests that
therapeutic decisions should be made on an individual basis,
taking into account the patient’s overall clinical status and
preferences, and should not be based merely on chronologi-
cal age. It is therefore necessary to determine which elderly
patients are likely to benefit from active cancer therapy, and
the establishment of treatment markers for multimodality
approaches is eagerly awaited.
There is also clear evidence to indicate that elderly patients
are more susceptible to postoperative infections than young-
er patients, which may be related to the pro-inflammatory
status of elderly patients.1 Elderly patients with cancer are
also at risk of exposure to various intrinsic inflammatory
mediators, such as tumor-generating cytokines and sur-
gery-induced pro-inflammatory cytokines. It is therefore
important to understand the immunological changes occur-
ring in the elderly and to adjust treatment strategies accord-
ingly to reduce the morbidity and mortality associated with
cancer therapies that induce systemic inflammation.
Increasing evidence that host or immune responses are im-
portant prognostic indicators has been associated with the
development of a variety of prognostic scores based on the
presence of the systemic inflammatory response. The Glas-
gow Prognostic Score (GPS), an inflammation-based score
that includes serum C-reactive protein (CRP) and albumin
levels, is currently one of the most useful prognostic indica-
tors in patients with advanced cancer.4 Although the reasons
why elevated CRP correlates with poor long-term outcome
in cancer patients is not fully understood, several
pro-inflammatory cytokines expressed in the tumor envi-
ronment, such as interleukin-1(IL-1), IL-6, and tumor necro-
sis factor-α, may affect the malignant potential of tumor
cells.5 IL-6 is known to stimulate the acute-phase expression
of CRP. We previously reported that metabolic compliance
against intrinsic IL-6 may be compensated for in the stable
preoperative period, but may deteriorate as a result of surgi-
cal stress in elderly CRC patients with malnutrition.6
These results also suggest that the change in systemic in-
flammatory response during cancer therapy might reflect
compromised immunity in elderly patients with CRC. In-
deed, we detected a change in modified GPS after chemo-
therapy in patients with CRC, suggesting that modified GPS
may thus be a potential prognostic marker in elderly patients
receiving multimodality therapy.3, 7 GPS is simply a marker
of inflammation, and the cause-effect relationship between a
systemic inflammatory response and cancer survival is also
uncertain; however, the combination of several inflamma-
tion-based factors might reflect the balance between tumor
progression and host-related immunity, especially in elderly
cancer patients.
In conclusion, chronological age alone should not be a con-
traindication to multimodality cancer therapy in elderly
patients with CRC, and the use of active multimodality
therapy may be a valuable approach for improving survival
in these patients. Furthermore, appropriate selection criteria
for multimodality therapy in elderly CRC patients may in-
clude not only tumor characteristics, but also host- and/or
treatment-related factors such as comorbidities or surrogate
markers such as GPS.
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